I would like to share some new(?) information on monoclonal antibody as following;
Study Results Suggest Ustekinumab May Trigger Acute CV Events Early in Treatment
September 18, 2020
Initiating treatment with the interleukin-12/23p40–targeting monoclonal antibody ustekinumab may trigger early severe cardiovascular events (SCEs) in susceptible patients, according to a large French case-time-control analysis.
Investigators led by Florence Poizeau, MD, of the department of dermatology at Rennes (France) University Hospital, found high-risk patients had more than four times the risk of an acute SCE in the 6 months after starting treatment. Although ustekinumab (Stelara) effectively treats moderate to severe psoriasis, psoriatic arthritis (PsA), and Crohn's disease (indications approved by the Food and Drug Administration), the early months after ustekinumab initiation may be associated with atherosclerotic plaque destabilization via the inhibition of helper T cell subtype 17, the group reported in JAMA Dermatology.
The observational study drew on France's 66 million–registrant health insurance database to identify all patients exposed to ustekinumab between April 1, 2010, and Dec. 31, 2016. Classified by high or low cardiovascular risk level, ustekinumab recipients served as their own controls, being compared during two time windows: the risk period covered the 6 months after initiating treatment and leading up to the SCE, defined as acute coronary syndrome (ACS) or stroke, while a reference period spanned the 6-12 months leading up to the risk period.
In the statistical analysis of 9,290 ustekinumab-exposed patients (mean age 43 years, 52% male), conducted from September 2017 to July 2018, 7,588 (82%) received ustekinumab for psoriasis or PsA, and 724 (8%) for Crohn's disease. (The remaining indications were for psoriasis or PsA and Crohn's disease, or were undetermined.)
Of these patients, 98 experienced SCEs (52 with ACS admitted to the ICU and 46 with strokes). In patients deemed at high cardiovascular risk – those with two risk factors or a personal history of atherosclerotic disease – there was a statistically significant association between starting ustekinumab and SCE occurrence, for an odds ratio of 4.17 (95% confidence interval, 1.19-14.59). In contrast, no such association emerged in ustekinumab users at low cardiovascular risk, for an OR of 0.30 (95% CI, 0.03-3.13). The OR for all was 2.41 (95% CI, 0.83-7.01).
Of the 98 patients included in the final case-time-control analysis, 62 were men (63%), the median age was 57 years, and 76 (78%) were at high cardiovascular risk. A total of 89 patients (91%) had psoriasis, four (4%) had Crohn's disease, and two (2%) had both.
The investigators also did an analysis including these 98 patients plus 13 patients with ACS who were not hospitalized in an ICU, and 68 with unstable angina, for a total of 179. In this group, the ORs for SCE were 1.75 (95% CI, 0.86-3.56) overall, compared with 3.20 (95% CI, 1.29-7.92) among those at high cardiovascular risk and 0.21 (95% CI, 0.02-1.69) among those at low cardiovascular risk.
The Rennes investigators' decision to focus on early SCEs stemmed in part from a meta-analysis of randomized clinical trials that reported a possible excess of early SCEs in adults exposed to anti–IL-12/23p40 antibodies, which at that time included the now-discontinued experimental antibody briakinumab. Briakinumab trials were aborted and the drug was never brought to market, leaving ustekinumab as the only antibody of this type.
All the best,
|Notice||How to write your comments onto a webpage ||2016.07.06||운영자||2016.11.20||13544|
|Notice||How to Upload Pictures in webpages||2016.07.06||운영자||2018.10.19||1976|
|Notice||How to use Rich Text Editor ||2016.06.28||운영자||2018.10.19||1224|
|Notice||How to Write a Webpage ||2016.06.28||운영자||2018.10.19||1201|
|7456||Key Facts about Seasonal Flu Shots 20220-21,CDC ||2020.10.21||이한중*65||2020.10.21||7|
|7455||Second Wave hits Eastern Europe hard! ||2020.10.21||이병붕*63||2020.10.21||22|
|7454||Death of 28 yr old Resident MD exposes Harsh Realities ||2020.10.21||이한중*65||2020.10.21||23|
|7453||과연 중국이 미국의 적일 까? ||2020.10.21||온기철*71||2020.10.21||17|
|7452||한국 독감 예방주사 밎은 후 4명 사망 ||2020.10.20||온기철*71||2020.10.21||27|
|7451||The most interesting 60 Minutes in case you missed it||2020.10.20||온기철*71||2020.10.20||25|
|7450||Great Barrington Declaration vs John Snow Memorandum ||2020.10.20||이한중*65||2020.10.21||15|
|7449||Neuroscience says No Surprise Victory for Trump This Time ||2020.10.20||이한중*65||2020.10.21||43|
|7448||자주국방과 자주국가 ||2020.10.20||온기철*71||2020.10.21||28|
|7447||한-일-중의 미묘한 관계 -한사람의 의견 ||2020.10.19||운영자||2020.10.20||47|
|7446||공무도하가 황조가 ||2020.10.19||최광택*70||2020.10.20||52|
|7445||蜀相 (촉상): 촉한승상 제갈량 ||2020.10.19||정관호*63||2020.10.21||44|
|7444||What Did Newton Actuality Discover in Quarantine? ||2020.10.18||이한중*65||2020.10.19||30|
|7443||What Would Boccaccio Say About COVID19? ||2020.10.18||이한중*65||2020.10.19||78|
|7442||천 년 전 한국 땅에 또 다른 문자가 있었다 ||2020.10.17||운영자||2020.10.20||73|
|7441||전시 작전권 ||2020.10.17||온기철*71||2020.10.18||18|
|7440||[Medical]Autopsy Findings of Heart and Lung on 40 COVID19 Patients ||2020.10.17||이한중*65||2020.10.17||31|
|7439||Be More Gentle with Yourself ||2020.10.16||이한중*65||2020.10.17||30|
|7438||Astronauts' Deep Sense of Hatred Towards Humanity ||2020.10.16||이한중*65||2020.10.17||27|
|7437||Europe On the Brink of Disaster ||2020.10.16||이한중*65||2020.10.17||38|